Persistence of an atherogenic lipid profile after treatment of acute infection with brucella

Journal of Lipid Research

Volumn 50, Issue 12, 2009, Pages 2532-2539

  Apostolou, F ^a   Gazi, I F ^a   Kostoula, A ^b   Tellis, C C ^c   Tselepis, A D ^c   Elisaf, M ^a   Liberopoulos, E N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cholesterol ester transfer protein; Cytokines; Lipoprotein associated phospholipase A2; Oxidized low density lipoprotein; Paraoxonase 1; Small dense low density lipoprotein

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; DOXYCYCLINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIFAMPICIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATHEROGENESIS; BRUCELLA; BRUCELLOSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE DISEASE; ADMINISTRATION, ORAL; ATHEROSCLEROSIS; BRUCELLA MELITENSIS; BRUCELLOSIS; CASE-CONTROL STUDIES; DOXYCYCLINE; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RIFAMPIN;

EID: 70849115338     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P900063-JLR200     Document Type: Article

References (68)

1. Frishman, W. H., and A. A. Ismail. 2002. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol. Rev. 10: 199-210.
2. Rufail, M. L., H. A. Schenkein, S. E. Barbour, J. G. Tew, and R. van Antwerpen. 2005. Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis. J. Lipid Res. 46: 2752-2760.
3. Adiloglu, A. K., R. Can, C. Nazli, A. Ocal, O. Ergene, G. Tinaz, and N. Kisioglu. 2005. Ectasia and severe atherosclerosis: relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers. Tex. Heart Inst. J. 32: 21-27.
4. Cuffini, C., L. Alberto Guzman, N. Villegas, C. Eduardo Alonso, L. Martinez-Riera, M. Rodriguez-Fermepin, A. Carolina Entrocassi, M. Pilar Adamo, M. Pedranti, and M. Zapata. 2006. Isolation of Chlamydophila pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile. Enferm. Infecc. Microbiol. Clin. 24: 81-85.
5. Ferrari, M., G. S. Werner, B. M. Richartz, A. Oehme, E. Straube, and H. R. Figulla. 2005. Lack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteries. Cardiovasc. Ultrasound. 3: 12.
6. Khairy, P., S. Rinfret, J. C. Tardif, R. Marchand, S. Shapiro, J. Brophy, and J. Dupuis. 2003. Absence of association between infectious agents and endothelial function in healthy young men. Circulation. 107: 1966-1971.
7. Haider, A. W., P. W. Wilson, M. G. Larson, J. C. Evans, E. L. Michelson, P. A. Wolf, C. J. O'Donnell, and D.levy. 2002. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J. Am. Coll. Cardiol. 40: 1408-1413.
8. Fong, I. W. 2000. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ. 163: 49-56.
9. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196.
10. Barlage, S., D. Frohlich, A. Bottcher, M. Jauhiainen, H. P. Muller, F. Noetzel, G. Rothe, C. Schutt, R. P. Linke, K. J. Lackner, et al. 2001. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J. Lipid Res. 42: 281-290.
11. Liberopoulos, E., G. Alexandridis, E. Bairaktari, and M. Elisaf. 2002. Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann. Clin. Lab. Sci. 32: 305-308.
12. Mooser, V., M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero. 2000. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler. Thromb. Vasc. Biol. 20: 1137-1142.
13. Wu, A., C. J. Hinds, and C. Thiemermann. 2004. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock. 21: 210-221.
14. Liberopoulos, E., F. Apostolou, and M. Elisaf. 2004. Serum lipid profi le in patients with severe leptospirosis. Nephrol. Dial. Transplant. 19: 1328-1329.
15. Memon, R. A., I. Staprans, M. Noor, W. M. Holleran, Y. Uchida, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2000. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20: 1536-1542.
16. Barter, P. 2000. CETP and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2029-2031.
17. Tselepis, A. D., and M. John Chapman. 2002. Infl ammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3: 57-68.
18. Packard, C., M. Caslake, and J. Shepherd. 2000. The role of small, dense low density lipoprotein (LDL): a new look. Int. J. Cardiol. 74 (Suppl. 1): S17-S22.
19. Kugiyama, K., Y. Ota, K. Takazoe, Y. Moriyama, H. Kawano, Y. Miyao, T. Sakamoto, H. Soejima, H. Ogawa, H. Doi, et al. 1999. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 100: 1280-1284.
20. Memon, R. A., J. Fuller, A. H. Moser, K. R. Feingold, and C. Grunfeld. 1999. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am. J. Physiol. 277: R94-R103.
21. Khovidhunkit, W., R. A. Memon, J. K. Shigenaga, M. Pang, M. Schambelan, K. Mulligan, K. R. Feingold, and C. Grunfeld. 1999. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism.. 48: 1524-1531.
22. Trimoreau, F., B. Francois, A. Desachy, A. Besse, P. Vignon, and Y. Denizot. 2000. Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome. Mediators Inflamm. 9: 197-200.
23. Mackness, M. I., B. Mackness, and P. N. Durrington. 2002. Paraoxonase and coronary heart disease. Atherosclerosis. 3: 49-55.
24. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-infl ammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
25. Horoz, M., M. Aslan, S. Selek, A. O. Koylu, C. Bolukbas, F. F. Bolukbas, H. Celik, and O. Erel. 2007. PON1 status in haemodialysis patients and the impact of hepatitis C infection. Clin. Biochem. 40: 609-614.
26. Cabana, V. G., C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz. 2003. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J. Lipid Res. 44: 780-792.
27. St-Pierre, A. C., I. L. Ruel, B. Cantin, G. R. Dagenais, P. M. Bernard, J. P. Despres, and B. Lamarche. 2001. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104: 2295-2299.
28. Gazi, I. F., V. Tsimihodimos, A. D. Tselepis, M. Elisaf, and D. P. Mikhailidis. 2007. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin. Biol. Ther. 7: 53-72.
29. Griffi n, B. A., D. J. Freeman, G. W. Tait, J. Thomson, M. J. Caslake, C. J. Packard, and J. Shepherd. 1994. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 106: 241-253.
30. Gardner, C. D., S. P. Fortmann, and R. M. Krauss. 1996. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276: 875-881.
31. Khovidhunkit, W., R. A. Memon, K. R. Feingold, and C. Grunfeld. 2000. Infection and infl ammation-induced proatherogenic changes of lipoproteins. J. Infect. Dis. 181 (Suppl. 3): S462-S472.
32. Badiou, S., C. Merle De Boever, A. M. Dupuy, V. Baillat, J. P. Cristol, and J. Reynes. 2003. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 168: 107-113.
33. Pappas, G., N. Akritidis, M. Bosilkovski, and E. Tsianos. 2005. Brucellosis. N. Engl. J. Med. 352: 2325-2336.
34. Tsouli, S. G., D. N. Kiortsis, E. S. Lourida, V. Xydis, L. D. Tsironis, M. I. Argyropoulou, M. Elisaf, and A. D. Tselepis. 2006. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J. Lipid Res. 47: 2208-2214.
35. Ordovas, J. M., L. A. Cupples, D. Corella, J. D. Otvos, D. Osgood, A. Martinez, C. Lahoz, O. Coltell, P. W. Wilson, and E. J. Schaefer. 2000. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler. Thromb. Vasc. Biol. 20: 1323-1329.
36. Georgiadis, A. N., E. C. Papavasiliou, E. S. Lourida, Y. Alamanos, C. Kostara, A. D. Tselepis, and A. A. Drosos. 2006. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res. Ther. 8: R82.
37. Tselepis, A. D., C. Dentan, S. A. Karabina, M. J. Chapman, and E. Ninio. 1995. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15: 1764-1773.
38. Liberopoulos, E. N., E. Papavasiliou, G. A. Miltiadous, M. Cariolou, K. C. Siamopoulos, A. D. Tselepis, and M. S. Elisaf. 2004. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit. Dial. Int. 24: 580-589.
39. Filippatos, T. D., I. F. Gazi, E. N. Liberopoulos, V. G. Athyros, M. S. Elisaf, A. D. Tselepis, and D. N. Kiortsis. 2007. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 193: 428-437.
40. Hoefner, D. M., S. D. Hodel, J. F. O'Brien, E. L. Branum, D. Sun, I. Meissner, and J. P. McConnell. 2001. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin. Chem. 47: 266-274.
41. Gazi, I., E. S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A. D. Tselepis. 2005. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. 51: 2264-2273.
42. Vermont, C. L., M. den Brinker, N. Kakeci, E. D. de Kleijn, Y. B. de Rijke, K. F. Joosten, R. de Groot, and J. A. Hazelzet. 2005. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit. Care Med. 33: 1610-1615.
43. Fraunberger, P., G. Pilz, P. Cremer, K. Werdan, and A. K. Walli. 1998. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock. 10: 359-363.
44. van Leeuwen, H. J., E. C. Heezius, G. M. Dallinga, J. A. van Strijp, J. Verhoef, and K. P. van Kessel. 2003. Lipoprotein metabolism in patients with severe sepsis. Crit. Care Med. 31: 1359-1366.
45. Fraunberger, P., J. Hahn, E. Holler, A. K. Walli, and D. Seidel. 2002. Serum cholesterol levels in neutropenic patients with fever. Clin. Chem. Lab. Med. 40: 304-307.
46. Hudgins, L. C., T. S. Parker, D. M. Levine, B. R. Gordon, S. D. Saal, X. C. Jiang, C. E. Seidman, J. D. Tremaroli, J. Lai, and A. L. Rubin. 2003. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J. Lipid Res. 44: 1489-1498.
47. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold. 1992. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodefi ciency syndrome. J. Clin. Endocrinol. Metab. 74: 1045-1052.
48. Gordon, B. R., T. S. Parker, D. M. Levine, S. D. Saal, J. C. Wang, B. J. Sloan, P. S. Barie, and A. L. Rubin. 2001. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit. Care Med. 29: 1563-1568.
49. Gierens, H., M. Nauck, M. Roth, R. Schinker, C. Schurmann, H. Scharnagl, G. Neuhaus, H. Wieland, and W. Marz. 2000. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler. Thromb. Vasc. Biol. 20: 1777-1783.
50. van Leeuwen, H. J., A. P. van Beek, G. M. Dallinga-Thie, J. A. van Strijp, J. Verhoef, and K. P. van Kessel. 2001. The role of high density lipoprotein in sepsis. Neth. J. Med. 59: 102-110.
51. Kwong, L. K., D. N. Ridinger, M. Bandhauer, J. H. Ward, W. E. Samlowski, P. H. Iverius, H. Pritchard, and D. E. Wilson. 1997. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J. Clin. Endocrinol. Metab. 82: 1572-1581.
52. Chenaud, C., P. G. Merlani, P. Roux-Lombard, D. Burger, S. Harbarth, S. Luyasu, J. D. Graf, J. M. Dayer, and B. Ricou. 2004. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit. Care Med. 32: 632-637.
53. Packard, C. J., D. S. O'Reilly, M. J. Caslake, A. D. McMahon, I. Ford, J. Cooney, C. H. Macphee, K. E. Suckling, M. Krishna, F. E. Wilkinson, et al. 2000. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343: 1148-1155.
54. Endo, S., K. Inada, H. Yamashita, T. Takakuwa, H. Nakae, T. Kasai, M. Kikuchi, M. Ogawa, K. Uchida, and M. Yoshida. 1994. Platelet-activating factor (PAF) acetylhydrolase activity, type II phospholipase A2, and cytokine levels in patients with sepsis. Res. Commun. Chem. Pathol. Pharmacol. 83: 289-295.
55. Takakuwa, T., S. Endo, H. Nakae, T. Suzuki, K. Inada, M. Yoshida, M. Ogawa, and K. Uchida. 1994. Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84: 271-281.
56. Karasawa, K., A. Harada, N. Satoh, K. Inoue, and M. Setaka. 2003. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog. Lipid Res. 42: 93-114.
57. Graham, R. M., C. J. Stephens, W. Silvester, L. L. Leong, M. J. Sturm, and R. R. Taylor. 1994. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit. Care Med. 22: 204-212.
58. Howard, K. M., and M. S. Olson. 2000. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J. Biol. Chem. 275: 19891-19896.
59. Narahara, H., and J. M. Johnston. 1993. Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am. J. Obstet. Gynecol. 169: 531-537.
60. Tumurkhuu, G., N. Koide, K. Takahashi, F. Hassan, S. Islam, H. Ito, I. Mori, T. Yoshida, and T. Yokochi. 2006. Characterization of biological activities of Brucella melitensis lipopolysaccharide. Microbiol. Immunol. 50: 421-427.
61. Casao, M. A., R. Diaz, A. Orduna, and C. Gamazo. 2001. Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies. J. Med. Microbiol. 50: 965-968.
62. Kilic, S. S., S. Aydin, N. Kilic, F. Erman, S. Aydin, and I. Celik. 2005. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J. Gastroenterol. 11: 7351-7354.
63. Parra, S., C. Alonso-Villaverde, B. Coll, N. Ferre, J. Marsillach, G. Aragones, M. Mackness, B. Mackness, L. Masana, J. Joven, et al. 2007. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis. 194: 175-181.
64. Aslan, M., Y. Nazligul, M. Horoz, C. Bolukbas, F. F. Bolukbas, M. Gur, H. Celik, and O. Erel. 2008. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 196: 270-274.
65. Feingold, K. R., R. A. Memon, A. H. Moser, and C. Grunfeld. 1998. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 139: 307-315.
66. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26: 892-904.
67. Mackness, B., P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 107: 2775-2779.
68. Ribalta, J., J. C. Vallvé, J. Girona, and L. Masana. 2003. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr. Opin. Clin. Nutr. Metab. Care. 6: 177-187.